Assessing Genetic Expression Profiles in Melanoma Prognosis - 07/09/17
, Alex M. Glazer, MD b, Richard R. Winkelmann, DO c, Darrell S. Rigel, MD, MS dRésumé |
A 31-genetic expression profile (31-GEP) test (DecisionDx-Melanoma, Castle Biosciences Inc, Friendswood, TX, USA) was developed as a diagnostic test to assist physicians in the management of cutaneous malignant melanoma. Based on a patient’s primary tumor expression levels of a panel of genes (28 discriminating genes and 3 control genes), a lesion is classified as “low risk” (class 1) or “high risk” (class 2) for metastasis. Studies evaluating the clinical utility and impact of the 31-GEP test showed it positively influenced clinical management and patient care, as clinicians incorporated the additional data to modify their clinical recommendations in a risk-appropriate manner.
Le texte complet de cet article est disponible en PDF.Keywords : Skin cancer, Melanoma, Prognosis, DecisionDx-melanoma, Genetic expression profile
Plan
| Disclosure Statement: Dr A.S. Farberg: Served as a consultant to Castle Biosciences Inc. Dr A.M. Glazer: Participated in a research fellowship that was partially funded by Castle Biosciences Inc. Dr R.R. Winkelmann: None. Dr D.S. Rigel: Served as a consultant to Castle Biosciences Inc. |
Vol 35 - N° 4
P. 545-550 - octobre 2017 Retour au numéro
Article précédent
- Assessing Genetic Expression Profiles in Melanoma Diagnosis
- Sancy A. Leachman, Stephanie Mengden Koon, Veselina B. Korcheva, Kevin P. White
- Smartphone-Based Applications for Skin Monitoring and Melanoma Detection
- Elizabeth Chao, Chelsea K. Meenan, Laura K. Ferris
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?